The phase II DEBBRAH trial evaluated TDXd in HER2-positive breast cancer in distinct cohorts, including patients with stable BM treated with local therapy, patients with asymptomatic and untreated BM, patients with progressive BM refractory to local therapy, and patients with LM. Here, ERBB2 is linked to breast cancer.